Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03622385 · ClinicalTrials.gov registry record
Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer
A clinical trial, sponsored by Baylor Research Institute.
- Completed
- Registry status
- 10
- Enrollment target
NCT03622385: Completed study, sponsored by Baylor Research Institute.
NCT03622385 is a clinical trial that has completed, run by Baylor Research Institute. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03622385 has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if there are markers in plasma that can be used to develop a diagnostic panel for early detection and diagnosis of high grade serous epithelial ovarian cancer.
Primary Outcome
Isolate DNA using QiaAMp DNA mini kits from tissue and plasma samples from subjects with serous epithelial ovarian cancer and normal subjects and then sequence the DNA using HiSeq Genome Analyzer. The investigators will identify the sequence reads using Illumina base-calling software and analyze them using Zymo Research proprietary analysis pipeline to identify differences in genomic expression in normal subjects compared to subjects with Serous Epithelial Ovarian Cancer.
Interventions
- OTHER DNA Methylation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-02-19 |
| Est. Completion | 2021-09-28 |
What the finished NCT03622385 record still lists
NCT03622385 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which DNA Methylation is the first listed.
NCT03622385 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03622385 about?
NCT03622385 is a clinical study titled "Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer". The purpose of this study is to determine if there are markers in plasma that can be used to develop a diagnostic panel for early detection and diagnosis of high grade serous epithelial ovarian cancer.
What is the current status of trial NCT03622385?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2019-02-19. Estimated completion is 2021-09-28.
What interventions are being tested in trial NCT03622385?
The interventions under investigation include: DNA Methylation (OTHER).
Who is sponsoring clinical trial NCT03622385?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI